Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). Methods SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-res...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi, The Swiss Group for Clinical Cancer Research (SAKK)
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	BMC 2017-04-01
Serie:	BMC Cancer
Ämnen:	ER-positive early breast cancer Adjuvant treatment recommendation Multigene expression profiling Recurrence score Oncotype DX
Länkar:	http://link.springer.com/article/10.1186/s12885-017-3261-1
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!